All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Down for the Count in AML: Understanding the Mechanisms By Which AML Blasts Might Induce Cytopenias
In a recent issue of Blood, Aaron D. Goldberg and Martin S. Tallman provided a commentary on the work by Rauch et al. relating to a decline in non-leukemic hematopoiesis in the bone marrow of patients with Acute Myeloid Leukemia (AML).
According to Goldberg and Tallman the majority of patients with AML present with cytopenias in 1 or more cell lineages. Yet, despite many hypotheses, the mechanism by which healthy hematopoiesis is disrupted in AML still needs to be elucidated.
The research by Rauch et al. provided further understanding of the mechanisms by which AML blasts might induce cytopenias. Primarily their findings challenged the notion that AML spatially displaces non-leukemic hematopoiesis from the bone marrow. They reported that, based on the examination of 223 AML patients, they did not identify a relationship between bone marrow blast content and cytopenia. However, they do state that cytopenia is strongly predicted by MPL expression on blast cells.
They further investigated the pathogenesis of peripheral blood cytopenia by measuring the serum concentration Thrombopoietin (TPO), the regulator of hematopoietic stem cells and megakaryocytes. They reported that MPLhi blasts scavenge TPO from the serum, which results in insufficient cytokine levels for non-leukemic hematopoiesis.
However, Tallman and Goldberg do not believe that TPO scavenging by MPL is the only determinant of cytopenias in AML patients. Although, they still affirm that the research by Rauch et al. of great significance for the following reasons:
“[The research] supports an intriguing and novel model to explain the impairment of normal hematopoiesis in patients with AML. By stealing TPO, high levels of MPL on AML blasts might leave AML patients down for the count.”
The full article by Goldberg Tallman from Blood can be found here
References
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?